newsfilter
← Latest News
Earnings Call Transcripts·

Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - OCUGEN INC

Good morning, and welcome to OxyGEN's webcast to discuss the top-line 12-month results from Phase II Armada Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-Related Macular Degeneration.

Company
OCUGEN INC
Keywords
OCUGEN INC